Exhibit
10.5


 


DIRECTOR
AGREEMENT


 


This
DIRECTOR AGREEMENT (the “Agreement”) is dated [●] (the “Effective Date”) by and between ASP
Isotopes Inc., a Delaware corporation (the “Company”), and [●], an individual resident in [●] (the “Director”).


 


WHEREAS,
the Company appointed the Director effective as of the Effective Date and desires to enter into an agreement with the Director with respect
to such appointment; and


 


WHEREAS,
the Director is willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with the
provisions of this Agreement.


 


NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:


 


1.
Position. The Company has caused the Director to be appointed as a member of the Company’s Board of Directors (the “Board”)
as of the Effective Date, and the Director hereby agrees to serve the Company in such position upon the terms and conditions hereinafter
set forth.


 


2.
Duties. During the Directorship Term (as defined herein), the Director shall perform such duties and responsibilities as are customarily
performed by a director, and shall have all responsibilities of a director imposed by Delaware or other applicable law, the Company’s
Certificate of Incorporation and Bylaws, each as may be amended, including:


 


		●	using
best efforts to attend scheduled meetings of the Board;



 


		●	serving
on committees of the Board as reasonably requested by the Board;



 


		●	participating
as a full voting member of the Board in setting overall objectives, approving plans and programs of operation, formulating general policies,
offering advice and counsel, and reviewing management performance; and



 


		●	representing
the shareholders and the interests of the Company as a fiduciary.



 


3.
Compensation.


 


There
will be two components of compensation – a Fee and a Stock Award. The Fee and the Stock Award represent complete payment for all
services by the Director.


 


(a)
Fee. The Company shall pay the Director a fee for services hereunder of Sixty Thousand Dollars ($60,000) per annum (the “Board
Compensation”). A lump sum initial payment of Board Compensation (the “Initial Payment”) will be made twelve
months after the Effective Date on October 13th, 2022 (the “Initial Payment Date”), provided the Director continues
to serve through such date. Following the Initial Payment, Board Compensation will be paid in arrears in equal quarterly installments
of Fifteen Thousand Dollars ($15,000) (the “Quarterly Payments”). Quarterly Payments shall be due on the last business
day of each December, March, June and September in the Directorship Term hereof (the “Payment Dates”). The Board Compensation
shall be paid either in readily available funds or fully paid, validly issued and non-assessable common stock of the Company (the “Common
Stock”), at the sole option of the Director, to be exercised by written notice to the Company on or prior to the Payment Date,
failing which the Board Compensation shall be paid in cash. In the event that a Quarterly Payment is to be remitted in Common Stock,
the number of shares shall be determined by dividing the Initial Payment or the Quarterly Payment by either (i) the fair market value
per share of Common Stock, as determined in good faith by the Board, or (ii) the closing sale price of the Common Stock on the trading
day immediately preceding the applicable Payment Date, as reported by the principal trading market for the Common Stock. During the first
year, should the Directorship terminate early for “good reason”, (“good reason” being defined as i) death,
ii) disability or serious extended physical or mental illness, iii) resignation on mutually acceptable good terms for personal reasons),
the Director will be eligible for a pro-rata amount of the Initial Payment. If the Directorship terminates early for any other reason,
the Director will not be entitled to any Board Compensation.


 



     


    


    

 


(b)
Common Stock Award. The Director shall be granted Common Stock (the “Common Stock Award”) with a value of One
Hundred Thousand Dollars ($100,000) annually. The first Common Stock Award will be made on the Initial Payment Date and subsequent Common
Stock Awards will be made annually thereafter for the duration of the Directorship Term. The number of shares granted in the Common Stock
Award shall be determined by dividing $100,000 by either (i) the fair market value per share of Common Stock, as determined in good faith
by the Board, or (ii) the closing sale price of the Common Stock on the trading day immediately preceding the applicable Payment Date,
as reported by the principal trading market for the Common Stock.


 


(c)
Independent Contractor. The Director’s legal status during the Directorship Term shall be that of an independent contractor
and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration
made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the
Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.


 


(d)
Expense Reimbursements. During the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket
expenses incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally
applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of
such expenses. Any reimbursements for any single item of expense in excess of $1,500 or for aggregate expenses during any thirty-day
period in excess of $3,000 must be approved in advance by the Company.


 


4.
Directorship Term. The “Directorship Term,” as used in this Agreement, shall mean the period commencing on
the Effective Date and terminating on the earlier of (a) the date of the annual stockholders meeting that occurs after October 26, 2024
(the date of such annual stockholder’s meeting, the “Term Date”) or (b) the first to occur of (i) the death
of the Director; (ii) the termination of the Director from his membership on the Board by the mutual agreement of the Company and the
Director; (iii) the removal of the Director from the Board by the stockholders of the Company; (iv) the resignation by the Director from
the Board; or (v) the date Director ceases for any other reason to be a member of the Board. In the event that the Director is re-elected
at any annual stockholders meeting, then the Term Date shall be extended to the first annual stockholders meeting occurring after such
re-election.


 


5.
Director’s Representation and Acknowledgment. The Director represents to the Company that his execution and performance
of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person
or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement
(and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have
no recourse whatsoever against any stockholder of the Company or any of their respective affiliates with regard to this Agreement.


 






    2


    


    

 


6.
Director Covenants.


 


(a)
Unauthorized Disclosure. The Director agrees and understands that in the Director’s position with the Company, the Director
will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, research
programs and results, data, scientific concepts, inventions and technical information (collectively, “Company IP”),
business and marketing plans, strategies, customer information, other information concerning the Company’s research and development
activities, products, promotions, development, financing, expansion plans, business policies and practices, and other forms of information
considered by the Company to be confidential and in the nature of trade secrets. The Director agrees that during the Directorship Term
and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or indirectly,
to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director
shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company’s industry
other than as a result of the Director’s breach of his obligations hereunder and (ii) the Director may, after giving prior notice
to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws
or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical or territorial
restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy at the Company’s
direction all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards,
surveys, maps, logs, machines, technical data, other product or document, and any summary or compilation of the foregoing, in whatever
form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director
in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term, provided
that the Company shall retain such materials and make them available to the Director if requested by him in connection with any litigation
against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the
materials are useful to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction
of the Company.


 


(b)
Non-Solicitation. During the Directorship Term and for a period of three (3) years thereafter, the Director shall not interfere
with the Company’s relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination
of the Directorship Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee,
contractor, service provider, customer, or vendor of the Company or otherwise had a material business relationship with the Company.


 


(c)
No Conflict. Director will not engage in any activity that creates an actual or perceived conflict of interest with the Company,
regardless of whether such activity is prohibited by Company’s conflict of interest guidelines or this Agreement, and Director
agrees to immediately notify the Board before engaging in any activity that could reasonably be assumed to create a potential conflict
of interest with Company. Director shall not engage in any activity that is in direct competition with the Company or serve in any capacity
(including, but not limited to, as an employee, consultant, advisor or director) in any company or entity that competes directly or indirectly
with the Company without the approval of the disinterested members of the Board. Nothing in this Section 6(c) shall prohibit the Director
from being (i) a stockholder in a mutual fund or a diversified investment company or (ii) a passive owner of any class of securities
of a corporation, which are either private or publicly traded, so long as the Director has no active participation in the business of
such corporation or (iii) serving as an employee, consultant, director, advisor or board member of any other company that does not engage
in any activity that is in direct competition with the Company.


 






    3


    


    

 


(d)
Remedies. The Director agrees that any breach of the terms of this Section 6 would result in irreparable injury and damage to
the Company for which the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said
breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach
and/or threatened breach and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without
having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity.
The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach
hereof, including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not
have entered into this Agreement had the Director not agreed to the provisions of this Section 6.


 


(e)
During the Directorship Term, and at all times thereafter, Director shall cooperate with the Company, at the Company’s sole cost
and expense (not including legal fees and expenses that Director may incur by retaining independent counsel), with respect to matters
about which Director has knowledge, including, without limitation (i) matters involving any review, audit or investigation by the Company
and (ii) any pending or threatened claim, demand, action, cause of action, suit, litigation, or administrative or arbitral proceeding,
hearing or review, including, without limitation, any request from a regulatory or similar agency, involving the Company.


 


(f)
The provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action
by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of the covenants and agreements of this Section 6.


 


7.
Work Product. In the event that the Director participates in any of the Company’s research and development activities (“Company
Practice”), or pursues research and development activities that are premised on, or extensions of, in whole or in part, research
or development activities carried on by the Company (“Derivative Practice”), then the Company shall own all right,
title and interest relating to all inventions, improvements, discoveries, methods, developments, software, and works of authorship, whether
patentable or not, which are created, made, conceived or reduced to practice by the Director or jointly with others and are either materially
derivative from Company Practice or Derivative Practice or involved Director’s use of Company IP (collectively, “Developments”).
The Director agrees to make full and prompt disclosure to the Company of all Developments and provide all Developments and all materials
and concepts relating to Developments to the Company. Director hereby assigns to the Company or its designee all of the Director’s
right, title and interest in and to any and all Developments. The Director agrees to cooperate fully with the Company, both during and
after the term of this Agreement, with respect to the procurement, maintenance and enforcement of intellectual property rights (both
in the United States and foreign countries) relating to any Developments. The Director shall sign all documents which may be necessary
or desirable in order to protect the Company’s rights in and to any Developments, and the Director hereby irrevocably designates
and appoints each officer of the Company as the Director’s agent and attorney-in-fact to execute any such documents on the Director’s
behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in
any Developments. Notwithstanding anything to the contrary above, this Section 7 does not apply to an invention for which no equipment,
supplies, facility of the Company or Company IP was used, unless the invention relates to the business of the Company or to the Company’s
actual or demonstrably anticipated research or development, or the invention results from any work performed by the Director for the
Company.


 






    4


    


    

 


8.
Indemnification; Insurance. Simultaneous with the execution of this Director Agreement, the Company and the Director will execute
an Indemnification Agreement providing for the Company to indemnify the Director for his activities as a member of the Board or any committee
of the Board to the fullest extent permitted under the laws of the State of Delaware.


 


9.
Notices. Every notice relating to this Agreement shall be in writing and shall be given by personal delivery or by email with
a read receipt; to:


 


If
to the Company:


 


Attn:
Chairman


ASP
Isotopes Inc.


433
Plaza Real, Suite 275


Boca
Raton, FL. 33432


Email:
pmann@aspisotopes.com


 


If
to the Director at the address set forth below the Director’s signature hereto.


 


Either
of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant
to this Section 9.


 


10.
Binding Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns. Notwithstanding
the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion of this Agreement
without the prior written consent of the other party.


 


11.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without
reference to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard
and determined in any court in Delaware and the parties hereto hereby consent to the jurisdiction of such courts in any such action or
proceeding; provided, however, that neither party shall commence any such action or proceeding unless prior thereto the
parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject of such action or proceeding
through mediation by an independent third party.


 


12.
Modifications. Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument
in writing duly signed by the party to be charged.


 


13
Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed to be an original but both of
which together shall constitute one and the same instrument.


 


[Signature
Page Follows]


 




    5


    


    

 


IN
WITNESS WHEREOF, the parties hereto have executed this Director Agreement on and as of the day and year first above written.


 


	 	ASP ISOTOPES, INC.
	 	 
	 	 
	 	Paul Mann
	 	Chief Executive Officer
	 	 
	 	DIRECTOR
	 	 
	 	 
	 	[Name]
	 	 
	 	Address: 
	 	 
	 	 
	 	 
	 	 
	 	Email: 
	 	 


 


[Signature Page to Director Agreement]